Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: Incorporating cytochrome P450 3A activity measurements

A. C. Hooker, A. J. Ten Tije, Michael A Carducci, J. Weber, E. Garrett-Mayer, H. Gelderblom, W. P. McGuire, J. Verweij, M. O. Karlsson, S. D. Baker

Research output: Contribution to journalArticle

Abstract

The relationship between cytochrome P4503A4 (CYP3A4) activity and docetaxel clearance in patients with varying degrees of liver function (LF) was evaluated. Docetaxel 40, 50, or 75 mg/m2 was administered to 85 patients with advanced cancer; 23 of 77 evaluable patients had abnormalities in LF tests. Baseline CYP3A activity was assessed using the erythromycin breath test (ERMBT). Pharmacokinetic studies and toxicity assessments were performed during cycle 1 of therapy and population modeling was performed using NONMEM. Docetaxel unbound clearance was lower (317 vs. 470 l/h) and more variable in patients with LF abnormalities compared to patients with normal LF. Covariates evaluated accounted for 83% of variability on clearance in patients with liver dysfunction, with CYP3A4 activity accounting for 47% of variation; covariates accounted for only 23% of variability in patients with normal LF. The clinical utility of the ERMBT may lie in identifying safe docetaxel doses for patients with LF abnormalities.

Original languageEnglish (US)
Pages (from-to)111-118
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume84
Issue number1
DOIs
StatePublished - Jul 2008

Fingerprint

docetaxel
Cytochrome P-450 CYP3A
Pharmacokinetics
Liver
Population
Breath Tests
Erythromycin
Cytochromes
Liver Function Tests
Liver Diseases

ASJC Scopus subject areas

  • Pharmacology

Cite this

Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function : Incorporating cytochrome P450 3A activity measurements. / Hooker, A. C.; Ten Tije, A. J.; Carducci, Michael A; Weber, J.; Garrett-Mayer, E.; Gelderblom, H.; McGuire, W. P.; Verweij, J.; Karlsson, M. O.; Baker, S. D.

In: Clinical Pharmacology and Therapeutics, Vol. 84, No. 1, 07.2008, p. 111-118.

Research output: Contribution to journalArticle

Hooker, A. C. ; Ten Tije, A. J. ; Carducci, Michael A ; Weber, J. ; Garrett-Mayer, E. ; Gelderblom, H. ; McGuire, W. P. ; Verweij, J. ; Karlsson, M. O. ; Baker, S. D. / Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function : Incorporating cytochrome P450 3A activity measurements. In: Clinical Pharmacology and Therapeutics. 2008 ; Vol. 84, No. 1. pp. 111-118.
@article{a049af7f315145198380b20318c7e380,
title = "Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: Incorporating cytochrome P450 3A activity measurements",
abstract = "The relationship between cytochrome P4503A4 (CYP3A4) activity and docetaxel clearance in patients with varying degrees of liver function (LF) was evaluated. Docetaxel 40, 50, or 75 mg/m2 was administered to 85 patients with advanced cancer; 23 of 77 evaluable patients had abnormalities in LF tests. Baseline CYP3A activity was assessed using the erythromycin breath test (ERMBT). Pharmacokinetic studies and toxicity assessments were performed during cycle 1 of therapy and population modeling was performed using NONMEM. Docetaxel unbound clearance was lower (317 vs. 470 l/h) and more variable in patients with LF abnormalities compared to patients with normal LF. Covariates evaluated accounted for 83{\%} of variability on clearance in patients with liver dysfunction, with CYP3A4 activity accounting for 47{\%} of variation; covariates accounted for only 23{\%} of variability in patients with normal LF. The clinical utility of the ERMBT may lie in identifying safe docetaxel doses for patients with LF abnormalities.",
author = "Hooker, {A. C.} and {Ten Tije}, {A. J.} and Carducci, {Michael A} and J. Weber and E. Garrett-Mayer and H. Gelderblom and McGuire, {W. P.} and J. Verweij and Karlsson, {M. O.} and Baker, {S. D.}",
year = "2008",
month = "7",
doi = "10.1038/sj.clpt.6100476",
language = "English (US)",
volume = "84",
pages = "111--118",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function

T2 - Incorporating cytochrome P450 3A activity measurements

AU - Hooker, A. C.

AU - Ten Tije, A. J.

AU - Carducci, Michael A

AU - Weber, J.

AU - Garrett-Mayer, E.

AU - Gelderblom, H.

AU - McGuire, W. P.

AU - Verweij, J.

AU - Karlsson, M. O.

AU - Baker, S. D.

PY - 2008/7

Y1 - 2008/7

N2 - The relationship between cytochrome P4503A4 (CYP3A4) activity and docetaxel clearance in patients with varying degrees of liver function (LF) was evaluated. Docetaxel 40, 50, or 75 mg/m2 was administered to 85 patients with advanced cancer; 23 of 77 evaluable patients had abnormalities in LF tests. Baseline CYP3A activity was assessed using the erythromycin breath test (ERMBT). Pharmacokinetic studies and toxicity assessments were performed during cycle 1 of therapy and population modeling was performed using NONMEM. Docetaxel unbound clearance was lower (317 vs. 470 l/h) and more variable in patients with LF abnormalities compared to patients with normal LF. Covariates evaluated accounted for 83% of variability on clearance in patients with liver dysfunction, with CYP3A4 activity accounting for 47% of variation; covariates accounted for only 23% of variability in patients with normal LF. The clinical utility of the ERMBT may lie in identifying safe docetaxel doses for patients with LF abnormalities.

AB - The relationship between cytochrome P4503A4 (CYP3A4) activity and docetaxel clearance in patients with varying degrees of liver function (LF) was evaluated. Docetaxel 40, 50, or 75 mg/m2 was administered to 85 patients with advanced cancer; 23 of 77 evaluable patients had abnormalities in LF tests. Baseline CYP3A activity was assessed using the erythromycin breath test (ERMBT). Pharmacokinetic studies and toxicity assessments were performed during cycle 1 of therapy and population modeling was performed using NONMEM. Docetaxel unbound clearance was lower (317 vs. 470 l/h) and more variable in patients with LF abnormalities compared to patients with normal LF. Covariates evaluated accounted for 83% of variability on clearance in patients with liver dysfunction, with CYP3A4 activity accounting for 47% of variation; covariates accounted for only 23% of variability in patients with normal LF. The clinical utility of the ERMBT may lie in identifying safe docetaxel doses for patients with LF abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=45549101956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549101956&partnerID=8YFLogxK

U2 - 10.1038/sj.clpt.6100476

DO - 10.1038/sj.clpt.6100476

M3 - Article

C2 - 18183036

AN - SCOPUS:45549101956

VL - 84

SP - 111

EP - 118

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -